Reunion Neuroscience is participating in the 2025 Maternal Mental Health (MMH) FORUM to discuss RE104, its lead product candidate for treating postpartum depression (PPD). The company’s participation highlights the ongoing Phase 2 RECONNECT clinical trial, which is evaluating the safety and efficacy of a single dose of RE104 for moderate-to-severe PPD. This forum allows Reunion to present its research to policymakers, payers, and providers, aiming to improve maternal mental health care.
Maternal mental health disorders, impacting a significant number of expecting and postpartum mothers, represent a substantial unmet need. Reunion’s presence at the MMH FORUM underscores the critical importance of developing new treatment options. The forum offers a platform to discuss critical issues in maternal mental health care and showcase potential solutions like RE104, potentially leading to improved diagnosis and treatment standardization across the healthcare system.
RE104 is a prodrug of 4-OH-DiPT, designed to induce a shorter psychedelic experience than traditional psychedelics like psilocybin, while maintaining a similar safety and efficacy profile. The RECONNECT trial is a multicenter, randomized, double-blind, active dose-controlled study. Reunion is also planning the REKINDLE Phase 2 trial to evaluate RE104 for adjustment disorder in patients with cancer and other medical illnesses.
Reunion’s participation in the MMH FORUM and the ongoing RECONNECT trial position RE104 as a potential game-changer in the treatment of PPD. The data generated from this trial, along with future studies like REKINDLE, will be crucial in determining the efficacy and broader applicability of this novel therapeutic approach for various mental health disorders. This research has the potential to reshape the landscape of mental health care, particularly for underserved populations like postpartum mothers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
